SG Americas Securities LLC Buys 20,792 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

SG Americas Securities LLC increased its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 149.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,670 shares of the company’s stock after acquiring an additional 20,792 shares during the quarter. SG Americas Securities LLC’s holdings in Ventyx Biosciences were worth $76,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norden Group LLC acquired a new position in shares of Ventyx Biosciences in the 1st quarter worth approximately $59,000. Acadian Asset Management LLC acquired a new position in Ventyx Biosciences in the second quarter valued at $608,000. Deerfield Management Company L.P. Series C lifted its holdings in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after buying an additional 2,287,570 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ventyx Biosciences during the first quarter valued at $72,000. Finally, Cubist Systematic Strategies LLC grew its holdings in Ventyx Biosciences by 165.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after acquiring an additional 93,247 shares during the period. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Performance

Shares of NASDAQ:VTYX opened at $2.31 on Tuesday. The firm has a market cap of $163.25 million, a P/E ratio of -0.83 and a beta of 0.36. Ventyx Biosciences, Inc. has a 52-week low of $1.79 and a 52-week high of $15.81. The business’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $2.98.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. On average, equities analysts forecast that Ventyx Biosciences, Inc. will post -2.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wells Fargo & Company cut their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Tuesday, October 15th. Finally, Canaccord Genuity Group reduced their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.29.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.